Table 2.
Lamivudine (3TC) or emtricitabine (FTC) use in people in whom change to antiretroviral therapy (ART) (or initiation if treatment‐naïve) was recorded within 1 year of first detection of the M184V/I mutation and who were recorded in the data set for analysis of time‐to‐event outcomes [requiring viral load (VL) follow‐up and baseline CD4 count and VL]
| Year of ART change | On 3TC | On FTC | Not on 3TC/FTC | Total | |||
|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | |
| 1997 | 37 | 56.1 | 0 | 0 | 29 | 43.9 | 66 |
| 1998 | 48 | 31.2 | 0 | 0 | 106 | 68.8 | 154 |
| 1999 | 86 | 35.8 | 0 | 0 | 154 | 64.2 | 240 |
| 2000 | 90 | 34.4 | 0 | 0 | 172 | 65.6 | 262 |
| 2001 | 64 | 26.9 | 0 | 0 | 173 | 73.0 | 237 |
| 2002 | 56 | 28.7 | 0 | 0 | 139 | 71.3 | 195 |
| 2003 | 50 | 32.3 | 1 | 0.6 | 104 | 67.1 | 155 |
| 2004 | 43 | 27.4 | 1 | 0.6 | 113 | 72.0 | 157 |
| 2005 | 32 | 24.4 | 13 | 9.9 | 86 | 65.6 | 131 |
| 2006 | 26 | 19.5 | 28 | 21.1 | 79 | 59.4 | 133 |
| 2007 | 33 | 25.2 | 38 | 29.0 | 60 | 45.8 | 131 |
| 2008 | 20 | 15.7 | 62 | 48.8 | 45 | 35.4 | 127 |
| 2009 | 11 | 11.2 | 51 | 52.0 | 36 | 36.7 | 98 |
| 2010 | 15 | 18.1 | 29 | 34.9 | 39 | 47.0 | 83 |
| 2011 | 11 | 13.4 | 40 | 48.8 | 31 | 37.8 | 82 |
| 2012 | 5 | 9.1 | 24 | 43.6 | 26 | 47.3 | 55 |
| 2013 | 13 | 15.7 | 43 | 51.8 | 27 | 32.5 | 83 |
| 2014 | 8 | 17.0 | 24 | 51.1 | 15 | 31.9 | 47 |
| 2015 | 4 | 6.7 | 37 | 61.7 | 19 | 31.7 | 60 |
| 2016 | 6 | 10.3 | 38 | 65.5 | 14 | 24.1 | 58 |
| 2017 | 7 | 16.3 | 29 | 67.4 | 7 | 16.3 | 43 |
| Total | 665 | 25.6 | 458 | 17.6 | 1474 | 56.8 | 2597 |
Of those people on FTC, nearly all were on tenofovir (TFV)‐containing regimens, the exceptions being two in 2005 and one each in 2009 and 2016.